Am J Psychiatry 158:1982-1988, December 2001
© 2001 American Psychiatric Association
Efficacy and Safety of Paroxetine Treatment for Chronic PTSD: A Fixed-Dose, Placebo-Controlled Study
Randall D. Marshall, M.D.,
Katherine L. Beebe, Ph.D.,
Mary Oldham, Ph.D., and
Rocco Zaninelli, M.D.
OBJECTIVE: This study evaluated the efficacy and safety of paroxetine for the treatment of patients with chronic posttraumatic stress disorder (PTSD). METHOD: Outpatients with chronic PTSD according to DSM-IV criteria and a score of 50 or more on the Clinician-Administered PTSD Scale, part 2, were randomly assigned to take placebo (N=186), 20 mg/day of paroxetine (N=183), or 40 mg/day of paroxetine (N=182) for 12 weeks. Efficacy was assessed by examining the change in total score from baseline to endpoint on the Clinician-Administered PTSD Scale, part 2, and rates of response ("very much improved" or "much improved") for global improvement on the Clinical Global Impression scale. RESULTS: Paroxetine-treated patients in both dose groups demonstrated significantly greater improvement on primary outcome measures compared to placebo-treated patients in the intent-to-treat analysis. Moreover, paroxetine treatment resulted in statistically significant improvement compared to placebo on all three PTSD symptom clusters (reexperiencing, avoidance/numbing, and hyperarousal), social and occupational impairment, and comorbid depression. Paroxetine was effective for both men and women. Treatment response did not vary by trauma type, time since trauma, or severity of baseline PTSD or depressive symptoms. Both doses were well tolerated. CONCLUSIONS: Doses of 20 and 40 mg/day of paroxetine are effective and well tolerated in the treatment of adults with chronic PTSD.
This article has been cited by other articles:
|
|
|
|
 
C. B. Nemeroff, J. D. Bremner, E. B. Foa, H. S. Mayberg, C. S. North, and M. B. Stein
Posttraumatic Stress Disorder: A State-of-the-Science Review
Focus,
April 1, 2009;
7(2):
254 - 273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Itzhaky and R. Dekel
Community Intervention with Jewish Israeli Mothers in Times of Terror
Br. J. Soc. Work,
April 1, 2008;
38(3):
462 - 475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Bisson
Pharmacological treatment of post-traumatic stress disorder
Advan. Psychiatr. Treat.,
March 1, 2007;
13(2):
119 - 126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Davidson, D. Baldwin, D. J. Stein, E. Kuper, I. Benattia, S. Ahmed, R. Pedersen, and J. Musgnung
Treatment of Posttraumatic Stress Disorder With Venlafaxine Extended Release: A 6-Month Randomized Controlled Trial.
Arch Gen Psychiatry,
October 1, 2006;
63(10):
1158 - 1165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. B. Schoenfeld, C. R. Marmar, and T. C. Neylan
Current Concepts in Pharmacotherapy for Posttraumatic Stress Disorder
Psychiatr Serv,
May 1, 2004;
55(5):
519 - 531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Zatzick, P. Roy-Byrne, J. Russo, F. Rivara, R. Droesch, A. Wagner, C. Dunn, G. Jurkovich, E. Uehara, and W. Katon
A Randomized Effectiveness Trial of Stepped Collaborative Care for Acutely Injured Trauma Survivors
Arch Gen Psychiatry,
May 1, 2004;
61(5):
498 - 506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R.T. Davidson, D. J. Stein, A. Y. Shalev, and R. Yehuda
Posttraumatic Stress Disorder: Acquisition, Recognition, Course, and Treatment
J Neuropsychiatry Clin Neurosci,
May 1, 2004;
16(2):
135 - 147.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Cohen, Z. Kaplan, M. Kotler, I. Kouperman, R. Moisa, and N. Grisaru
Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex in Posttraumatic Stress Disorder: A Double-Blind, Placebo-Controlled Study
Am J Psychiatry,
March 1, 2004;
161(3):
515 - 524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. R. Peskind, L. T. Bonner, D. J. Hoff, and M. A. Raskind
Prazosin Reduces Trauma-Related Nightmares in Older Men with Chronic Posttraumatic Stress Disorder
J Geriatr Psychiatry Neurol,
September 1, 2003;
16(3):
165 - 171.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. M. Connor and M. I. Butterfield
Posttraumatic Stress Disorder
Focus,
July 1, 2003;
1(3):
247 - 262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. I Butterfield
Fluoxetine may prevent relapse in post traumatic stress disorder
Evid. Based Ment. Health,
May 1, 2003;
6(2):
51 - 51.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Stein
A 46-Year-Old Man With Anxiety and Nightmares After a Motor Vehicle Collision
JAMA,
September 25, 2002;
288(12):
1513 - 1521.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Paroxetine Is Effective for Chronic PTSD
Journal Watch Women's Health,
February 5, 2002;
2002(205):
12 - 12.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
